Long-acting reversible contraception side effect management

2020 ◽  
Vol 32 (4) ◽  
pp. 461-470
Author(s):  
Alexandra J. Edwards ◽  
Amy D. DiVasta ◽  
Sarah Pitts
Keyword(s):  
Side Effect ◽  
Long Acting

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

1996 ◽  
Vol 134 (4) ◽  
pp. 454-456 ◽  
Author(s):  
Etienne Delgrange ◽  
Dominique Maiter ◽  
Julian Donckier
Keyword(s):  
Internal Medicine ◽  
Side Effects ◽  
Dopamine Agonist ◽  
Side Effect ◽  
University Hospital ◽  
The Third ◽  
Group I ◽  
Resistant Group ◽  
Group Ii ◽  
Long Acting

Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–6. ISSN 0804–4643 Cabergoline is a new long-acting ergoline derivative used to treat hyperprolactinaemia. Its effect was assessed in 10 patients (eight women and two men) with prolactinoma who were intolerant (group I; N = 7) or resistant (group II; N = 3) to bromocriptine. In group I, no side effect was observed on cabergoline therapy; two patients became pregnant and normoprolactinaemia was achieved in the five others. In group II, cabergoline was active and well-tolerated in two out of the three patients: one woman had three consecutive pregnancies; in another patient normoprolactinaemia was restored and the tumour shrank by 60%; in the third patient cabergoline was discontinued because of side effects and inefficacy. Thus, cabergoline appears to be an alternative of choice as treatment of hyper-prolactinaemic patients who are intolerant or resistant to bromocriptine. Julian Donckier, Internal Medicine and Endocrinology, University Hospital UCL of Mont-Godinne, B-5530 Yvoir, Belgium

scholarly journals SAT-270 Priapism Secondary to Cabergoline

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Maryam Amir ◽  
Monica Flores ◽  
Jorge Calles-Escandon
Keyword(s):  
Side Effect ◽  
Penile Erection ◽  
Brain Mri ◽  
Sella Turcica ◽  
Underlying Mechanism ◽  
Recent Change ◽  
Low Flow ◽  
History Of ◽  
Long Acting ◽  
The Right

Abstract Background: Cabergoline and Bromocriptine are ergot derivative long-acting dopamine agonist that are very effective and well tolerated in patients with hyperprolactinemia. A rare and unwanted side effect of Bromocriptine is priapism, which has hardly ever been report in literature and it’s not cited under the medication insert. The underlying mechanism is not totally clear, but it is well known that dopaminergic pathways in the central nervous system are of importance for male sexual behavior and penile erection. Lesser is known about Cabergoline and priapism with only one case report in the literature (1). Clinical Case: A 65 yr old African American male with a past medical history significant for obesity, essential hypertension, and recent history of frontal headaches was found to have a pituitary macroadenoma. Brain MRI demonstrated 11 x 12 x 9 mm enhancing lesion within the right lateral sella turcica. The lesion extended laterally to abut the right cavernous ICA without vascular encasement or extension into the right temporal skull base. Prolactin level was 276.3 ng/mL (2.1-15.0 ng/mL). He was started on Cabergoline 0.5 mg weekly. 60 days after starting Cabergoline he presented to the ED with a painful penile erection lasting >12 hours. He did not take any Phosphodiesterase (PDE) inhibitors and had no other recent change in medications. He denied any history of sickle cell disease. His most recent dose of Carbergoline was the day prior to the ED visit. He was seen by a Urologist in the ED and confirmed to have a low flow Priapism and underwent aspiration of intracorporal bodies. He was discharged home on pseudoephedrine and pain medications. Carbergoline was discontinued. He has had no further episodes of Priapism since discontinuation of Cabergoline. Conclusion: The time between drug use and occurrence, absence of other offending medications or precipitating factors and no further priapism episodes once treatment was discontinued suggests a priapism as a rarely reported side effect of Cabergoline. (1) References: 1.E.de la Pena Zarzuelo, V. Hernandez Canas and C. Llorente Abarca, Department of Urology, Hospital Universitario Fundacion Alcorcon, Madrid, Spain

Efficacy and tolerability of switching to long-acting injectable (LAI) aripiprazole in outpatients with schizophrenia

2016 ◽  
Vol 33 (S1) ◽  
pp. s255-s256
Author(s):  
B. Fernández-Abascal Puente ◽  
M. Juncal Ruiz ◽  
R. Landera Rodríguez
Keyword(s):  
Side Effects ◽  
Treatment Regimen ◽  
Treatment Adherence ◽  
Side Effect ◽  
Negative Symptoms ◽  
Psychotic Symptoms ◽  
Oral Olanzapine ◽  
Insufficient Response ◽  
Competing Interest ◽  
Long Acting

IntroductionSwitching antipsychotics is a therapeutic alternative for managing side-effects, or efficacy and compliance issues.AimTo evaluate the efficacy and tolerability of switching to LAI-aripiprazole in patients who had insufficient response or were intolerant to the previous antipsychotic, or required a more convenient treatment regimen.MethodsThis was a prospective, observational, 6-months study carried out in 45 outpatients with schizophrenia who were clinically stabilized but a switching to another antipsychotic was clinically indicated. Patients who required hospitalization, treatment discontinuation or adding another antipsychotic (including supplementation with oral-aripiprazole) were considered treatment failures. Switching was considered successful if the side-effect/symptom/adherence/convenience improved or, if applicable, disappeared.ResultsPatients aged 38 years, 51% women, and previous antipsychotics comprised: LAI-paliperidone (42%), oral-aripiprazole (22%), oral-olanzapine (11%), oral-risperidone (7%), LAI-risperidone (4%) and others (14%). The efficacy results of the switching are presented in the table. Of the 45 patients, 7 (15%) were considered treatment failures: 3 patients were hospitalized due to recurrence of psychotic symptoms, 2 discontinued LAI-aripiprazole, and 2 required supplementation with oral-aripiprazole (Fig 1).ConclusionsOur results suggest that switching to LAI-aripiprazole is an efficacious strategy for managing some antipsychotic-induced side-effects, persistence of negative symptoms and/or lack of treatment adherence.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals The Role of Mirena (Intra-uterine progestogens), Other than Contraceptive benefits: Current Concepts and Practices

1970 ◽  
Vol 28 (3) ◽  
pp. 174-182
Author(s):  
I Bina
Keyword(s):  
Blood Loss ◽  
Side Effect ◽  
Inflammatory Diseases ◽  
Hormone Replacement ◽  
Uterine Cavity ◽  
Common Side Effect ◽  
Maximum Effect ◽  
Conflicting Evidence ◽  
Contraceptive System ◽  
Long Acting

Mirena is a long acting intrauterine hormone-releasing (LNG-IUS) contraceptive system with a flexible plastic T-shaped frame bearing a levonorgestrel(LNG)- containing cylinder which releases small doses levonorgestrel into the uterine cavity after insertion with maximum effect on the endometrium and minimum progestogenic side-effect. LNG causes thinning of the endometrium, atrophy of the endometrial glands and decidualisation of the endometrial stroma. The most common side-effect of LNG-IUS is unscheduled vaginal bleeding in the first 3 months, so proper counseling is needed. In some cases functional ovarian cysts may occur which are relatively small, symptomless and resolved spontaneously within a short time.Mirena is now licensed for the treatment of menorrhagia in UK because it reduces 97% of blood loss in 12 months uses. It is also an effective progestogenic endometrial protection in women with Hormone replacement therapy. There are conflicting evidence of LNG-IUS in the management of Fibroids uterus but it reduces fibroid related menstrual blood losses. It has also some beneficial effect in endometriosis and adenomyosis by reducing pain and blood loss. The LNG-IUS also reduces endometrial hyperplasia and may take place in the treatment of eartly endometrial cancer in some cases. The rate of ectopic pregnancy and pelvic inflammatory diseases are reduced in Mirena users compared with IUCD users.Keywords: Mirena; Intrauterine progestogens; Noncontraceptive; LNG-IUS DOI: 10.3329/jbcps.v28i3.6511J Bangladesh Coll Phys Surg 2010; 28: 167-173

G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives

2021 ◽  
Author(s):  
Marta Muzzana ◽  
Paolo Pedrazzoli ◽  
Angioletta Lasagna
Keyword(s):  
Side Effect ◽  
Early Recognition ◽  
Case Reports ◽  
Cochrane Library ◽  
Future Research ◽  
Cancer Type ◽  
Vascular Toxicity ◽  
Research Perspectives ◽  
Increased Risk ◽  
Long Acting

Background: There are several case reports suggesting that G-CSFs may, in rare conditions, produce serious side effects, such as vasculitis. Materials & methods: A systematic search was conducted in Medline via PubMed, Embase and Cochrane Library to describe this unusual side effect to raise awareness among clinicians for early recognition and treatment. Results: Fifty-seven patients were analyzed. The most prevalent cancer type was breast cancer (47%). Long-acting G-CSF was used in 38 patients (67%). Only 47% of patients were treated with steroids. Conclusion: Although the benefit of G-CSF treatment outweighs the potential damage, oncologists should consider the possibility of triggering a vascular toxicity and try to identify patients at increased risk for this side effect.

Sign in / Sign up

Export Citation Format

Share Document